Feminizing hormone therapy works by shifting your body’s dominant sex hormone from testosterone to estrogen. This is done through two complementary strategies: introducing estrogen from an external source and suppressing the testosterone your body naturally produces. The Endocrine Society and WPATH guidelines recommend targeting estradiol levels of 100 to 200 pg/mL and testosterone below 50 ng/dL, which mirrors the typical hormone profile of cisgender women.
How Estrogen and Anti-Androgens Work Together
Your body’s hormone production is controlled by a feedback loop between your brain and gonads called the hypothalamic-pituitary-gonadal (HPG) axis. When you introduce estrogen from outside the body, your brain detects the rising estrogen levels and responds by dialing back the signals that tell the testes to produce testosterone. This is the same feedback mechanism that regulates hormone levels in all bodies, just redirected with external hormones.
Estrogen alone often isn’t enough to fully suppress testosterone, which is why most regimens include an anti-androgen medication. These work through different mechanisms depending on the specific drug. Some block testosterone from binding to its receptors in tissues like skin and hair follicles, essentially preventing it from doing its job even if it’s still circulating. Others reduce the conversion of testosterone into its more potent form, dihydrotestosterone (DHT). A third category suppresses testosterone production directly. The combination of added estrogen and reduced testosterone activity is what drives the physical and emotional changes of feminization.
Delivery Methods and Why They Matter
Estrogen can be taken as a pill, applied as a patch or gel, or given by injection. The differences between these routes go beyond convenience.
Oral estrogen passes through the liver before reaching the rest of the body. This “first pass” through the liver triggers the production of clotting proteins, which is the primary reason oral estrogen carries a higher risk of blood clots. A large cohort study found that oral estrogen raised the risk of venous thromboembolism (VTE) by 2.7 times compared to cisgender women, while transdermal estrogen showed no significant increase. A meta-analysis in cisgender women confirmed this pattern: oral estrogen users had 1.9 times the VTE risk of nonusers, while transdermal users had essentially the same risk as nonusers (1.0 times).
Transdermal estrogen (patches and gels) absorbs directly through the skin into the bloodstream, bypassing the liver entirely. This means a lower dose can achieve the same blood levels, and the absence of that liver pass is why clotting factors stay closer to baseline. For anyone with existing risk factors for blood clots, such as smoking, obesity, or certain genetic mutations, transdermal delivery is considered substantially safer. In people with clotting mutations, oral estrogen raised VTE risk by over 25 times, while transdermal estrogen raised it by about 4 times.
Injections deliver estrogen directly into muscle or fat tissue, also avoiding the liver on first pass. They tend to produce higher peak levels that taper between doses, creating more of a hormonal roller coaster compared to the steadier levels from patches or gels.
Physical Changes and When They Happen
Feminization unfolds gradually over months and years, not weeks. Most changes follow a predictable pattern according to Mayo Clinic timelines.
Softer, less oily skin is one of the earliest shifts, beginning within 3 to 6 months and reaching its full effect in that same window. Breast development also starts at 3 to 6 months but continues for 2 to 3 years before reaching its full extent. Muscle mass decreases over a similar timeline, starting at 3 to 6 months and reaching its maximum change within 1 to 2 years. Body fat redistribution, the shift toward carrying fat at the hips, thighs, and buttocks rather than the abdomen, begins at 3 to 6 months but can take 2 to 5 years to fully develop.
Lowering testosterone to the female range also slows terminal hair growth in androgen-sensitive areas like the face and chest, though existing thick hair follicles typically need additional treatment like laser hair removal. Voice changes do not occur with estrogen therapy, since vocal cord thickening from prior testosterone exposure is permanent.
Effects on Bone Density
Estrogen plays a protective role in bone health for all bodies. It slows the activity of cells that break down bone while supporting the cells that build it. A meta-analysis of transgender women on hormone therapy found that lumbar spine bone mineral density increased with treatment. However, the loss of muscle mass that accompanies testosterone suppression can reduce the mechanical loading on bones over time, which is why some long-term studies have observed a higher prevalence of low bone mass in transgender women. The overall evidence is mixed and limited by small study sizes, but maintaining adequate calcium, vitamin D, and weight-bearing exercise remains important.
Mental Health and Emotional Changes
The emotional effects of feminizing hormone therapy are among the changes people notice earliest, and the clinical data backs up what many describe anecdotally. In a prospective study of 107 transgender individuals, the proportion showing symptoms of depression dropped from 42% to 22% over 12 months of treatment. Depression scores on standardized scales improved by more than half after 24 months in another study. Anxiety showed similarly striking improvements: one study found that the proportion of participants with clinically significant anxiety fell from 50% to 17% over the course of treatment.
These improvements likely reflect both the direct neurological effects of shifting hormone profiles and the psychological relief of living in a body that better matches one’s identity. Systematic reviews consistently find that hormone therapy is associated with increased quality of life, decreased depression, and decreased anxiety. Among adolescents, one study saw mean anxiety scores drop from 33.0 to 18.5 after one year.
Fertility Considerations
Feminizing hormone therapy suppresses sperm production. Most transgender women on hormone therapy are not producing mature sperm by the time of any subsequent surgery, and clinical guidelines have long described the effect as eventually leading to irreversible infertility. Current recommendations encourage banking sperm before starting hormones.
That said, more recent research has complicated the “irreversible” label. A study following nine transgender women who stopped hormone therapy found that all nine eventually produced viable sperm again, though the timeline varied widely. Six had sperm present in their first semen analysis after stopping, while the remaining three took 8, 10, and 17 months respectively. Three of four participants who stopped therapy specifically to conceive with their partners succeeded. There was no clear relationship between how long someone had been on hormones and how quickly fertility returned, though the sample size was small. The takeaway is that sperm banking before starting is still the safest option, but stopping hormones may restore fertility for some people.
Blood Clot Risk in Context
Blood clots are the most discussed safety concern with feminizing hormone therapy, so it helps to put the numbers in perspective. One retrospective study of 676 transgender individuals on oral estradiol found that only one person, or 0.15%, experienced a clot over nearly two years of follow-up. A meta-analysis of over 11,500 transgender individuals on oral estrogen reported an absolute VTE incidence of about 2 per 1,000 person-years. The risk is highest in the first year of use, where one meta-analysis found a relative risk of 3.49 compared to nonusers, dropping after that initial period.
Longer-term data paints a slightly different picture. After an average of 11.3 years on estrogen, about 6% of transgender individuals had experienced a thromboembolic event and another 6% had other cardiovascular problems. Older formulations like ethinyl estradiol, which is no longer recommended for gender-affirming care, carried significantly higher risks than the bioidentical estradiol used in modern regimens. The shift away from those formulations, combined with the growing use of transdermal delivery, has meaningfully improved the safety profile of feminizing hormone therapy.
Monitoring During Treatment
Hormone levels are typically checked every three months during the first year to fine-tune dosing, then every 6 to 12 months once levels stabilize. Blood tests track both estradiol and testosterone to confirm that each is reaching the target range. If you’re taking spironolactone as your anti-androgen, potassium levels need regular monitoring since the drug can cause potassium to rise. Blood pressure, weight, and kidney and liver function are also checked at routine intervals. Some clinicians monitor prolactin levels because estrogen therapy carries a theoretical risk of a benign pituitary growth called a prolactinoma, though this is rare.